Slow-release Effect Of Zoledronic Acid Mixed Bone Cement And Toxicity Studies Of Sustained Release Liquid On The Tumor Cells

Background: The incidence of bone tumors is nearly0.01%, surgical treatment is stillthe main treatment of bone tumors and causes fractures. Drug release of antibiotic bonecement mixed in more mature, but the bone cement carry zoledronic acid treatment of bonetumors has not been reported in experimental and clinical applications.Objective: To observe the bone cement mixed azole effect the release of the drugzoledronic acid, as well as sustained-release azole zoledronic acid zoledronic acid inhibitoryeffect on tumor cells. Proved bone cement mixing zoledronic acid specimen can effectivelyrelease zoledronic acid proved zoledronic acid sustained release solution was able to inhibitbreast cancer tumor cells selected. Provide theoretical and practical basis for the use of bonecement mixed azole zoledronic acid in the treatment of metastatic bone cancer patients.Methods: Preparation of Six different azole zoledronic acid concentration of the bonecement specimens.10g bone cement reagents are divided into six groups (0.5mg,1.25mg,2.5mg,3.75mg,5.0mg, and0mg) of zoledronic acid reagent uniformly mixed. Mix well andmade standard specifications bone cement modules. Length (12±0.1) mm, the diameter of astraight cylinder (6±0.1) mm. Distilled water stored at37℃identical5mL of steriledeionized water, each of distilled water for24h removed, and a new one to continue soaking,remove the distilled water as the sample was used for the HPLC drug release and cytotoxicitytest (MTT) observed inhibition of breast cancer cells.The cell growth inhibition rate=BA/B×100%(A represents the average opticaldensity of the experimental wells, B is the average density of control wells. Inhibition rate=1-survival).Results: The groups azole zoledronic acid bone cement release dose maximum within24h,48h, concentrations decreased rapidly and reached a plateau after4d. Released after twoweeks in an extremely small amount of state. The experiments show the release of zoledronicacid concentration and the rate of the bone cement mixing zoledronic acid ratio related to thesize, the overall was a positive relationship. MTT assay showed that zoledronic acid onbreast cancer cells cytotoxic, four days before the inhibitory effect is most obvious (P<0.05), its inhibitory effects on breast cancer cells for4weeks (P <0.05). Sustained releaseliquid concentration and the inhibition of tumor cell strength with zoledronic acid mixtureconcentration in the bone cement in a positive correlation. Conclusion: Zoledronic acid can be released from the bone cement, the sustained releaseliquid still has a biological activity. And sustained-release solution significantly inhibitedbreast cancer cells cultured in vitro. Release of zoledronic acid, the concentration and itsinhibitory effect on breast cancer cells and time correlation. The zoledronic acid mixed bonecement treatment of bone tumor disease operability,and theoretical and experimental basis forthe next animal experiments and clinical trials.